Patient selection
follicular lymphoma, DLBCL, endometrial carcinoma, bidimensionally measurable disease, midline carcinoma, transformed lymphoma, NHL
DISEASE PROGRESSION, SALIVARY GLAND CARCINOMA, FOLLICULAR LYMPHOMA, DISEASE, SOLID TUMORS, BCC, ENDOMETRIAL CARCINOMA, NHL
Patients were enrolled from July 31, 2017 to January 11, 2021. The study included patients aged ≥18 years with an ECOG PS of 0 or 1. Part A included patients with histologically or cytologically confirmed advanced or unresectable solid tumors or R/R advanced NHL that had progressed on standard anticancer therapy or for which no conventional therapy was available.Part B included patients with histologically or cytologically confirmed R/R DLBCL that had progressed following two or more previous lines of therapy, including autologous stem cell transplant, or that had progressed after at least one previous line of therapy and where the patient was not eligible for or had declined autologous stem cell transplant. Patients with transformed lymphoma following chemotherapy for follicular lymphoma who had received at least two standard treatment regimens for DLBCL were also eligible. Patients must have had a lack of response after chimeric antigen receptor (CAR) T-cell therapy (if available), been ineligible for CAR T-cell therapy, or declined CAR T-cell therapy. Part B also included a cohort of patients with histologically or cytologically confirmed advanced BCC, nuclear protein in testis (NUT) midline carcinoma, advanced salivary gland carcinoma, or advanced endometrial carcinoma and disease progression on, or inability to tolerate, standard therapy, or for whom no standard therapy exists. Patient enrollment in this cohort was subsequently restricted to patients with advanced BCC only in a protocol amendment.Part C included patients with histologically or cytologically confirmed advanced solid tumors and disease progression on, or inability to tolerate standard therapy, or for whom no standard therapy exists.Patients with solid tumors had at least one site of measurable disease; patients with NHL had bidimensionally measurable disease on cross-sectional imaging, with at least one lesion >1.5 cm in diameter.